SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (STEM)

• ClinicalTrials.gov Identifier: NCT02970682
• Recruitment Status: Completed
• First Posted: November 22, 2016
• Last Update Posted: July 12, 2019
• Sponsor: Evgen Pharma
• Collaborator: Premier Research Group plc
• Information provided by (Responsible Party): Evgen Pharma

Study Description

Brief Summary:

This is a Phase 2 study to demonstrate the safety and efficacy of SFX-01 when used in combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant.

Patients will be enrolled into one of three study arms (SFX-01 in combination with AI, tamoxifen or fulvestrant) based on their current therapy.

Condition or disease	Intervention/treatment	Phase
Breast Neoplasm	Drug: SFX-01; Drug: Fulvestrant; Drug: Tamoxifen; Drug: Aromatase Inhibitors	Phase 2

Detailed Description:

The trial is a phase 2, parallel group design in patients with ER positive metastatic breast cancer.

This study will be a multicentre study conducted over an 18 month period. Patients who are taking either a third generation AI, tamoxifen or fulvestrant and have a documented evidence of progressive disease after achieving a best response of stable disease (for at least 6 months) or an objective response of CR or PR on the current treatment indicating the development of secondary resistance to current therapy will be entered into the study having undergone a screening period to continue receiving the same treatment with the addition of SFX-01.

At least 60 patients will be enrolled into one of three arms in a 1:1:1 ratio, i.e. 20 patients per arm. Enrolment will be based on current treatment.

Treatment Arm A: All patients will continue to receive their AI and, at the start of the study (D1), patients will additionally take SFX-01.

Treatment Arm B: All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will additionally take SFX-01

Treatment Arm C: All patients will continue to receive fulvestrant 500 mg IM in 28 day Cycles and, at the start of the study (D1), patients will additionally take SFX-01.

Patient participation will include a Screening Phase, a Treatment Phase, and a Follow-up Phase of up to 28 weeks post D1 of dosing. The Screening Phase will be up to 28 days prior to enrolment. The Treatment Phase will extend from enrolment until the patient is discontinued from study treatment. The Follow-up Phase will be a maximum of 28 weeks and extend from the time of study entry until 30 days after the patient discontinues trial therapy.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
• Actual Study Start Date: October 2016
• Actual Primary Completion Date: January 2019
• Actual Study Completion Date: March 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Aromatase Inhibitor; SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).	Drug: SFX-01; Stabilised Sulforaphane; Other Name: Sulforadex; Drug: Aromatase Inhibitors
Experimental: Fulvestrant; SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).	Drug: SFX-01; Stabilised Sulforaphane; Other Name: Sulforadex; Drug: Fulvestrant; Fulvestrant
Experimental: Tamoxifen; SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).	Drug: SFX-01; Stabilised Sulforaphane; Other Name: Sulforadex; Drug: Tamoxifen; Tamoxifen

Outcome Measures

Primary Outcome Measures :

1. Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: 28 weeks ]
   To determine the safety and tolerability of SFX-01 in combination with AI, tamoxifen and fulvestrant
2. Clinical benefit rate [ Time Frame: 24 weeks ]
   To determine clinical benefit rate (CBR) (CR+PR+SD) at 24 weeks using RECIST v1.1

Secondary Outcome Measures :

1. Objective Response rate [ Time Frame: 24 Weeks ]
   To determine objective response rate (ORR) (CR+PR) at 24 weeks using RECIST v1.1
2. Time To Response [ Time Frame: 24 weeks ]
   To determine time to response
3. Time to Progression [ Time Frame: 24 Weeks ]
   To determine time to progression (TTP)
4. Progression Free Survival [ Time Frame: 24 Weeks ]
   To determine progression free survival (PFS) at 24 weeks
5. Overall Survival [ Time Frame: 24 Weeks ]
   To determine overall survival (OS) at 24 weeks
6. Clinical Benefit [ Time Frame: 24 Weeks ]
   To determine clinical benefit by measuring duration of response compared to duration of response to prior ET
7. Time to next Treatment [ Time Frame: 24 weeks ]
   To determine time to next treatment

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female patients 18 years or older (the patient must be the legal age limit to give informed consent within the jurisdiction the study is taking place in);
2. Patients with histologically confirmed estrogen receptor positive (ER+) breast cancer. ER is considered positive if a percentage score of ≥10% of tumour cells staining positive for ER;
3. Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. HER2 negative is defined by the ASCO/CAP guidelines;
4. Patients with clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection;
5. Patients must have at least one site of measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) ≥ 10 mm with spiral CT scan or MRI scan (malignant lymph nodes should be ≥15mm to be considered measurable); all sites of disease should be noted and followed in accordance with RECIST v1.1. (A lytic or mixed lytic-blastic bone lesion with a soft tissue component assessed on CT/MRI can be measurable if the minimum size criteria are met. Blastic bone lesions and bone lesions assessed on bone scan, positron emission therapy (PET) or plain films are non-measurable);
6. Patients must have an anticipated life expectancy of at least 12 weeks;

7. Adequate bone marrow, renal and hepatic function defined as:

   • Haemoglobin > 9 g/dL;
   • Absolute neutrophil count > 1.0 x 109/L;
   • Platelets > 100 x 109/L;
   • Total bilirubin within normal limits, except those with Gilberts syndrome for whom this must be <2.5 x ULN;
   • AST(SGOT) or ALT(SGPT) < 2.5 x ULN;
   • Calculated creatinine clearance > 30 ml/min (Appendix 2);
8. Eastern Cooperative Oncology Group (ECOG) performance status < 2;

9. Must currently be on either a third generation aromatase inhibitor, tamoxifen or fulvestrant and have a documented evidence of progressive disease after:

   1. taking ET as adjuvant therapy for >2 years or
   2. achieving a best response of stable disease (for at least 6 months) or an objective response of CR or PR on the current treatment both indicating the development of secondary resistance to current therapy;
10. Suitable for continuing endocrine therapy according to the treating clinician. The window of discontinuation must not exceed 4 weeks.
11. All patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
12. No more than 3 lines of endocrine therapy for metastatic/locally advanced breast cancer including the treatment that the patient is receiving at the time of study entry. This can include targeted agents alongside endocrine therapy such as, but not limited to, everolimus and palbociclib. Ovarian function suppression therapy is not an exclusion for females who are premenopausal and on an ET that can be continued throughout the study.
13. No more than one prior line of chemotherapy/targeted therapy for metastatic/locally advanced breast cancer.
14. Patients with adequately controlled hepatitis C or hepatitis B surface antigen.
15. No residual toxicity > grade 1 from prior antineoplastic therapy with the exception of peripheral neuropathy or neuropathic pain which must be stable (as per investigator assessment);
16. Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control (e.g., barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices) during the entire duration of the study and for 6 months after final administration of study drug. Note that sterility in female patients must be confirmed in the patients' medical records and be defined as any of the following: surgical hysterectomy or bilateral oophorectomy, bilateral tubular ligation, natural menopause with last menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with 1 year interval since last menses; male patients whose female partner(s) is (are) pregnant must use a condom from the time of the first administration of SFX-01 until 3 months following administration of last dose;
17. Female patients of childbearing potential must have a negative serum or urine pregnancy test at day 1 of the study.

Exclusion Criteria:

1. Rapidly progressive visceral disease not suitable for further endocrine therapy;
2. Currently on chemotherapy or any other combination treatment for their MBC other than AI, tamoxifen or fulvestrant;
3. Radiotherapy less than 2 weeks prior to study entry;
4. Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment;
5. Spinal cord compression or brain metastases unless treated and radiologically stable for > 6weeks post treatment and not requiring steroids for at least 4 weeks prior to start of study treatment;
6. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required;
7. Refractory nausea and vomiting, patients with malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications;
8. An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures;
9. Patients with unresolved or unstable serious toxicity from prior administration of another investigational drug and/or prior cancer treatment;
10. Diagnosed or treated for a malignancy other than breast cancer within 1 year, or who were previously diagnosed with a malignancy other than breast cancer and have any radiographic or biochemical marker evidence of malignancy. Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy (other than breast) are not excluded.
11. Concurrent treatment with another investigational agent or participated in another investigational trial unless adequate washout period per the investigational drug PK has been achieved (usually this is 5 half lives of a product);
12. Females who are pregnant, wishing to become pregnant or breast feeding.

Contacts and Locations

Locations

Belgium

Grand Hopital de Charleroi, Service D'Oncologie-Hematologie

Charleroi, Belgium, 6000

Saint-Luc hospital, Brussels

Woluwe-Saint-Lambert, Belgium, 1200

France

ICO René Gauducheau, St Herblain

Nantes, Loire Atlantique, France, 44805

Spain

Granollers Hospital, Granollers,

Barcelona, Spain

Hospital Universitario Ramon Y Cajal

Madrid, Spain, 100

United Kingdom

The Christie NHS Foundation Trust

Manchester, Greater Manchester, United Kingdom, M20 4BX

University Hospitals Birmingham NHS Foundation

Birmingham, United Kingdom, B15 2TH

Royal Bournemouth & Christchurch Hospitals NHS

Bournemouth, United Kingdom, BH7 7DW

Academic unit of Clinical Oncology

Sheffield, United Kingdom, S10 2SJ

Royal Albert & Edward Infirmary

Wigan, United Kingdom, WN1 2WN

Sponsors and Collaborators

Evgen Pharma

Premier Research Group plc

Investigators

• Principal Investigator: Sacha Howell, MD PhD; The Christie NHS Foundation Trust

More Information

• Responsible Party: Evgen Pharma
• ClinicalTrials.gov Identifier: NCT02970682
• Other Study ID Numbers: EVG001BC
• First Posted: November 22, 2016
• Last Update Posted: July 12, 2019
• Last Verified: June 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Tamoxifen; Fulvestrant; Aromatase Inhibitors; Estrogen Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Bone Density Conservation Agents; Estrogen Receptor Antagonists; Steroid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action